Δ-10-Tetrahydrocannabinol

Cardiac arrhythmias, Coronary artery disease, Heart failure

Tachycardia was reported in 23% of pooled Δ8/Δ10/THC-O poison center cases. While this data is predominantly Δ8-THC, the shared cannabinoid pharmacology suggests cardiovascular strain risk. Individuals with pre-existing cardiac conditions face elevated risk.

Major depressive disorder, Generalized anxiety disorder, History of suicidal ideation

The in vitro CB1 antagonist profile of Δ10-THC raises a theoretical psychiatric risk concern by pharmacological class parallel with rimonabant, which was withdrawn from the European market after association with depression, anxiety, and suicidal ideation. Whether Δ10-THC's weaker CB1 antagonism carries analogous risk at commercially relevant doses is unknown. No psychiatric adverse event data specific to Δ10-THC exist.

Warfarin therapy, Other CYP2C9-substrate anticoagulant therapy

By structural analogy to Δ9-THC, Δ10-THC is presumed to undergo hepatic metabolism via CYP2C9. Competition at this enzyme could elevate plasma concentrations of warfarin and related anticoagulants, increasing bleeding risk. INR monitoring is advisable if co-use occurs. The magnitude of CYP inhibition by Δ10-THC has not been measured.

No reproductive or developmental toxicity data exist for Δ10-THC. Cannabinoids as a class cross the placental barrier and are present in breast milk. Avoidance is the standard recommendation for all cannabinoid compounds pending substance-specific safety data.

Children are disproportionately represented in cannabinoid adverse event data. In pooled US poison center surveillance (2021–2022), children under 6 accounted for 30.1% of all Δ8/Δ10/THC-O exposures, with serious medical outcomes in 38.4% of cases. Peak exposure age was 2 years, with 94.2% of cases involving ingestion of edible products. Products must be stored inaccessibly to children.

No psychomotor impairment studies exist for Δ10-THC. General cannabinoid impairment of reaction time, coordination, and judgment applies by class inference. Additionally, Δ10-THC cross-reacts with all major commercial urine cannabinoid immunoassay screening kits (Wolf et al. 2023), meaning use will produce positive workplace drug test results regardless of actual impairment level.